Opioid-Induced Constipation：市場分析及び予測（～2017）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 11
1.2 List of Figures 13
2 Introduction 14
2.1 Catalyst 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 16
3.1.3 Quality of Life 17
3.2 Symptoms 18
3.2.1 The General Treatment Consensus in the US and EU 19
4 Potential Patient Population 21
4.1 Overview 21
4.2 General Forecast Methodology 22
4.3 Region-Specific Forecast Methodology 23
4.3.1 Opioid Consumption 23
4.3.2 Number of OIC Cases 24
4.4 Country-Level Differences in Opioid Consumption 25
4.4.1 US 25
4.4.2 France 28
4.4.3 Germany 31
4.4.4 Italy 33
4.4.5 Spain 36
4.4.6 UK 39
4.5 Potential Patient Population Forecast 42
4.5.1 Total Number of Cases of Opioid-Induced Constipation 42
5 Current Treatment Options 44
5.1 Overview 44
5.2 Product Profiles – Major Brands 49
5.2.1 Relistor 49
5.2.2 Targin 55
5.2.3 Amitiza 60
6 Unmet Needs Assessment and Opportunity Analysis 68
6.1 Overview 68
6.2 Unmet Needs Analysis 69
6.2.1 Lack of Efficacious, Targeted Treatment Options 69
6.2.2 Reimbursement for Non-Laxative Prescription OIC Therapies 69
6.2.3 Lack of Cost-Effective Treatment Options 71
6.2.4 Defined Treatment Guidelines for OIC 71
6.2.5 Improved Physician Awareness and Diagnosis of OIC 72
6.2.6 Improved Patient and Physician Awareness of Prescription Drugs Available for the Treatment of OIC 73
6.2.7 Clinical Data Assessing Laxative Efficacy 74
6.2.8 Parenteral Formulations of OIC Treatments for Patients in Intensive Care 75
6.3 Opportunity Analysis 75
6.3.1 Development of an Efficacious Drug without Adverse Effects or Compromised Analgesia 75
6.3.2 Label Expansion of Approved Constipation Drugs into OIC 76
6.3.3 Treatments that Target Other OBD Symptoms 76
6.3.4 Launch of an Extensive Physician Education Marketing Campaign 77
7 R&D Strategies 78
7.1 Overview 78
7.1.1 Increased Understanding of Drug Mechanism 78
7.1.2 Reformulation Strategies 78
7.1.3 Secondary Indications 79
7.1.4 Niche Patient Subgroups 79
7.1.5 Licensing and Alliances 79
7.2 Clinical Trial Design 80
7.2.1 Current Clinical Trial Design 80
7.2.2 Selection of Clinically Relevant Trial Endpoints 81
7.2.3 Demonstrating the Long-Term Safety of Mu Receptor Antagonists 81
8 Pipeline Assessment 83
8.1 Overview 83
8.2 Promising Drugs in Clinical Development 84
8.2.1 Naloxegol 85
8.2.2 Bevenopran (CB-5945) 89
8.2.3 Oral Relistor (MOA-728) 93
8.2.4 TD-1211 96
8.2.5 Naldemedine (S-297995) 98
8.2.6 Nalcol (oral naloxone) 100
8.2.7 Linzess (linaclotide) 103
8.2.8 Innovative Early-Stage Approaches 105
9 Pipeline Valuation Analysis 108
9.1 Clinical Benchmark of Key Pipeline Drugs 108
9.2 Commercial Benchmark of Key Pipeline Drugs 110
9.3 Competitive Assessment 111
9.4 Top-Line, Five-Year Forecast 112
9.4.1 US 115
9.4.2 5EU 116
10 Appendix 118
10.1 Bibliography 118
10.2 Abbreviations 122
10.3 Methodology 123
10.4 Forecast Methodology 123
10.4.1 Percent Drug-Treated Patients 124
10.4.2 Drugs Included in Each Therapeutic Class 124
10.4.3 Launch and Patent Expiry Dates 125
10.4.4 General Pricing Assumptions 126
10.4.5 Individual Drug Assumptions 126
10.4.6 Pricing of Pipeline Agents 129
10.5 Physicians and Specialists Included in this Study 129
10.6 About the Authors 131
10.6.1 Analyst, Cardiovascular and Metabolic Disorders 131
10.6.2 Therapy Director – CVMD and Infectious Disease 131
10.6.3 Global Head of Healthcare 131
10.7 About GlobalData 132
10.8 Disclaimer 132